ABSTRACT To determine mechanisms of benefit from diltiazem, 13 patients with coronary disease performed sustained isometric handgrip exercise and repeated the procedure during intravenous infusion of diltiazem (0.25 mg/kg bolus followed by 0.003 mg/kg/min). Cardiovascular responses to handgrip, diltiazem, their combination, and nitroglycerin were assessed by hemodynamic and electrocardiographic measurements and by computer-assisted measurements of normal and diseased segments of epicardial coronary arteries. Handgrip produced increases in heart rate (12%; p < .001), pulmonary arterial pressure (19%; p < .005), and pulmonary wedge pressure (33%; p < .005). Diltiazem produced significant reductions in heart rate (7%; p < .05) and aortic pressure (14%; p < .001). Pulmonary arterial pressure and pulmonary wedge pressure were unchanged by diltiazem. Diltiazem did not prevent the increase in heart rate or in aortic or wedge pressure associated with handgrip. Diltiazem prolonged atrioventricular conduction from 0.18 0.03 to 0.20 + 0.03 sec (p < .001). Compared with control values, nitroglycerin reduced aortic pressure (14%; p < .005), pulmonary arterial pressure (38%; p < .001), and pulmonary wedge pressure (42%; p < .005). Heart rate was unchanged. The constriction (20%) in lumen area of normal coronary arterial segments during handgrip was effectively prevented by infusion of diltiazem (1%; p < .001). Nitroglycerin produced a significantly greater increase (20%) in diameter of normal coronary arterial segments than diltiazem (3%; p < .001) and tended to have a more favorable effect than diltiazem on stenosis minimum area and flow resistance. The handgrip-induced constriction of minimum area and increase in stenosis flow resistance was prevented during diltiazem infusion. Diltiazem is a minimal epicardial coronary dilator compared with nitroglycerin, but it effectively blocks sympathetically mediated constriction of normal and diseased epicardial coronary arteries in human beings. Circulation 70, No. 3, 465-471, 1984. DILTIAZEM, a slow channel-blocking drug, is an effective agent for improving duration of exercise and reducing the signs and symptoms of myocardial ischemia in patients with exertional angina.' The mechanism of action is related in part to a reduction in submaximal myocardial oxygen 
DILTIAZEM, a slow channel-blocking drug, is an effective agent for improving duration of exercise and reducing the signs and symptoms of myocardial ischemia in patients with exertional angina.' The mechanism of action is related in part to a reduction in submaximal myocardial oxygen demand," 2 but other studies have suggested that oral diltiazem may improve myocardial blood flow during exertion in patients with exertional angina.3'4 This evidence was based on observations in noninvasive studies made during exercise testing. The calcium slow channelblocking drugs are frequently called "potent coronary vasodilators," although this perception is not well documented in humans. Diltiazem improves coronary sinus blood flow by 20% in animals,5 and one report indicated an increase in blood flow in humans during short-term intervention6; however, the change was not statistically significant.
To further define the mechanisms of diltiazem's apparent benefit to myocardial perfusion, the effects of intravenous diltiazem on systemic and pulmonary hemodynamics and on epicardial coronary arteries and stenoses in the resting state and during isometric handgrip exercise were measured. These effects were compared with those of sublingual nitroglycerin, a potent 
Methods
Patient selection. Eleven men and two women (mean age 57 + 6 years) participated in the study after signing an approved document of informed consent. Coronary arteriographic studies were performed for the evaluation of exertional angina in 11 patients and the other two patients were asymptomatic after bypass surgery. None of the patients had symptoms or histories consistent with coronary arterial spasm. Six patients had threevessel disease, two had two-vessel disease, four had one-vessel disease, and one had a mild (30% stenosis) right coronary lesion.
Study protocol. Twenty-four hours before study all cardiac medications were discontinued. Patients were studied in the fasting state and premedication with oral diazepam was used. A Swan-Ganz catheter was placed in the pulmonary artery and coronary arteriographic examination was performed with the Judkins technique. The diagnostic portion of the catheterization was completed and the video tape was reviewed. In each patient a vessel was selected for study on the basis of clear visualization of the area of stenosis without distortion by overlapping vessels. Cineangiograms of this vessel were made in the two perpendicular views that showed the anatomy and disease most clearly. Baseline hemodynamic measurements, including aortic pressure, pulmonary arterial pressure and pulmonary capillary wedge pressure, were made. Heart rate and PR interval were measured from the electrocardiogram recorded at 100 mm/sec paper speed.
Patients then performed sustained handgrip (4 min) at 25% of their predetermined maximal grip strength, using a hand ergometer. During the fourth minute hemodynamic variables and heart rate were recorded and a single injection of contrast medium into the coronary artery was made. Patients then rested until blood pressure and heart rate returned to control values. Diltiazem was then given as an intravenous bolus (0.25 mg/kg) followed by continuous infusion (0.003 mg/kg/min). This dose regimen was chosen to achieve steady-state plasma levels similar to those obtained with an oral dose of 360 mg/day; it was believed from clinical experience that patients tolerated this dose well and that it provided significant symptomatic benefit, whereas smaller oral doses of diltiazem were often ineffective.
Seven to 10 min after commencement of the diltiazem infusion, a new hemodynamic steady state was achieved, and hemodynamic and cineangiographic determinations were repeated. Patients then repeated the handgrip effort during continued diltiazem infusion. During the fourth minute hemodynamic and cineangiographic determinations were repeated. Blood samples were taken for measurement of plasma diltiazem levels8 during the control state and after 10 min of diltiazem infusion.
The diltiazem infusion was terminated and hemodynamic variables were allowed to return to baseline values. Sublingual nitroglycerin (0.4 mg) was then given and 3 to 5 min later hemodynamic and cineangiographic determinations were repeated. Nitroglycerin was chosen because this was previously shown to dilate epicardial coronary arteries.9 The study indicated that the effects of sublingual nitroglycerin on coronary arteries, measured 4 min after the doses, were similar to the effects of 0.05 mg of intracoronary nitroglycerin. Thus the use of nitroglycerin provided a comparison for the effect of diltiazem alone. The sequence of drug administration was not randomized because of the possibility of a carry-over effect of nitroglycerin obscuring the effects of diltiazem or handgrip. Nitroglycerin was used as a means of assessing the vasomobility of the coronary arteries, and this study was not designed to evaluate the effect of nitroglycerin on handgrip responses.
Analysis of angiograms. The methodology for computerized analysis of coronary arteriograms was described in detail previously. 7 The technique involved digitizing the borders of selected coronary arterial segments from a magnified projection of the cineangiogram. Corrections for pincushion distortion and magnification were made. Lumen diameter and area in normal and diseased segments were measured, with a dimensional accuracy of + 100 gm (SD). Percent diameter and area reduction in the stenosis and its flow resistance were estimated, assuming 1 ml/sec flow. An earlier study9 demonstrated the reproducibility of control measurements. Although absolute measurements were not validated in vivo, individual measurements are very reproducible, and in this study each patient served as his own control. Changes seen with intervention can therefore be attributed to the intervention. The previous study9 addressed the issue of the effect of contrast on coronary dimensions. When repeat angiograms were made 4 min after the prior injection no significant changes were detected.
In this study, both normal segments and stenosed segments were chosen for analysis. The normal segments were defined as vessels without lumen irregularities and were grouped according to cross-section area: large vessels >8 mm2, moderate vessels 4 to pressure (-5 mm Hg; p < .005) were all reduced significantly. Electrocardiographic studies. The control mean PR interval was 0.18 ± 0.03 sec and increased to 0.20 ± 0.03 sec (p < .001) during diltiazem infusion. None of the patients had PR intervals greater than 0.20 sec before diltiazem while six had first-degree heart block during the infusion; in no patient did a higher degree of block develop.
Angiographic studies. In figure 1 a series of computergenerated measurements of a coronary arterial segment is shown, illustrating the changes seen in one patient with the various interventions. In table 2 and figure 2 the effects of the various interventions on coronary lumen cross-sectional area are shown according to the vessel size. Handgrip resulted in a significant reduction in lumen area; the percentage reduction was greatest in the smaller vessels.
Diltiazem infusion produced no significant change in cross-sectional area compared with that during the resting state. The coronary constriction observed during handgrip alone was prevented with handgrip during diltiazem infusion.
Nitroglycerin produced an increase in the mean cross-sectional lumen area. The increase was significant for the largest vessels. Nitroglycerin had a significantly greater vasodilating effect on normal vessels than diltiazem (figure 2).
In figure 3 the relative changes in minimum area of mild stenoses (20% to 49%) and hemodynamically significant stenoses (50% to 90%) with handgrip, diltiazem, handgrip plus diltiazem, and sublingual nitroglycerin are shown. Handgrip produced a significant constriction of mild and hemodynamically significant lesions. The constriction 'with handgrip was significantly greater than that with handgrip plus diltiazem (p < .01). Nitroglycerin appeared to be a more potent dilator of the diseased arterial segments than diltiazem, but the difference'was not statistically significant.
Stenosis resistance was estimated with an assumed blood flow of 1 ml/sec. Compared with control, there was a significant increase in resistance during handgrip; this constriction was almost completely prevented by diltiazem (p < .05 for'mild stenoses; p < .02 for severe stenoses) as seen in figure 4 . Figure 4 also shows the changes with diltiazem and with nitroglycerin. Although nitroglycerin appeared to reduce stenosis resistance more effectively than diltiazem, the difference was not statistically significant.
The mean plasma level during diltiazem infusions was 154 + 68 ng/ml. Apart from the prolongation of the PR interval with diltiazem, no significant side ef- fects occurred as result of drug, handgrip exercise, or catheterization and angiographic examination.
Discussion
The response to isometric exercise in normal subjects is different from that in patients with coronary artery disease. 1'12 In both groups there is an increase in systemic pressure and heart rate; however, in the normal subjects there is a greater increase in cardiac output. This is a sympathetically mediated response; the increase in cardiac output is mediated via a-receptor stimulation, which is responsible for the increase in peripheral tone. In cardiac patients cardiac output does not increase to the same extent, primarily because of a fall in stroke volume, and there is a greater increase in peripheral resistance.
It is postulated that a-and /3-stimulation are centrally mediated neurogenic reflexes.13 Significant increases in plasma catecholamines occur with handgrip.14 5 In animals, coronary vessels constrict as a result of a-stimulation. [16] [17] [18] [19] In humans this stimulation is responsible for mediating the response to the coldpressor test20 and to isometric exercise.2' The importance of calcium influx as an integral part of the amediated constriction of coronary arteries has been demonstrated in animal studies,22 23 while calcium influx is less important in the constriction of peripheral arteries.
The changes with handgrip during infusion of diltiazem demonstrate the differential effect of calcium slow-channel blockade on a-adrenergic stimulation of peripheral and coronary vessels. There was a significant rise in mean arterial pressure, indicating that diltiazem did not prevent the a-mediated peripheral vasoconstriction while the reduction in coronary crosssectional area seen with handgrip alone was effectively prevented by diltiazem. Similar findings have been shown for nifedipine with the cold-pressor test24 and for verapamil with handgrip exercise.
The effects of handgrip in this study showed the predicted rise in heart rate and arterial pressure; the rise in filling pressure was less marked than that in a previously reported study but probably reflects differences in severity of coronary disease.25 In this study there was an 11% to 25% reduction in cross-sectional area of vessels with handgrip and a marked increase (103%) in flow resistance in significant (>50%) lesions. FIGURE 2. Effects of the study interventions on normal segments of three coronary vessels of different sizes (<4 mm2, 4 to 8 mm2, and >8 mm2). Data expressed as mean percentage change from control.
The effect of handgrip is compared with the effect of handgrip during intravenous infusion of diltiazem and the effect of diltiazem is compared with that of nitroglycerin. Paired t testing is used to test significance of difference. HGP = handgrip; DIL = diltiazem; NTG = nitroglycerin. With patients at rest, intravenous diltiazem had both direct cardiac and peripheral effects. Prolongation of atrioventricular conduction and slowing of heart rate occurred with a mean plasma diltiazem level of 154 ± 68 ng/ml. Similar effects on atrioventricular conduction and heart rate were reported previously with shortand long-term oral diltiazem.2 26, 27 Diltiazem produced a 12% reduction in mean arterial pressure, but there was no evidence of left ventricular dysfunction. Despite the direct cardiac and peripheral effects, diltiazem had no effect on the cross-sectional area of normal coronary arteries or stenoses in patients at rest. These findings may appear to be at variance with those of other studies in animals5 and in human experiments6 in which diltiazem improved myocardial blood flow. However, an increase in blood flow is caused by dilation of coronary resistance vessels rather than of the larger arteries that were measured in this study. influences. There is some evidence from animal studies to suggest that diltiazem may alter neurotransmission. 29 The potential therefore exists that the inhibitory effect of diltiazem on the sympathetically mediated vasoconstriction caused by handgrip observed in this study may be the result of partial blockade of sympathetic neurotransmission by diltiazem. Given the design of the study, it is not possible to definitively answer this question; however, this mechanism would not explain the differential effects on the peripheral and coronary circulation. After infusion of diltiazem, handgrip produced the same rise in systemic pressure presumably caused by peripheral constriction while the constriction in coronary arteries was prevented. Furthermore, studies in vitro23 that did not involve neurotransmission indicate that diltiazem blocks the norepinephrine-induced contraction of coronary arteries but has little effect on other blood vessels, suggesting that the effect is mediated via receptor-activated slow channels rather than by blockade of neurotransmission. It is well accepted that the reduction in caliber of epicardial coronary arteries with isometric exercise is an a-mediated response,'3' 21, 30 and the effects with diltiazem appear to be best explained on the basis of This study demonstrates that diltiazem has several potentially beneficial effects for treating patients with angina. In addition to reducing myocardial oxygen demand by lowering heart rate and blood pressure, the drug virtually prevents a-mediated vasoconstriction of normal and diseased segments of epicardial coronary arteries. It is speculated that vasoconstriction of epicardial coronary arteries occurs in some patients with exertional angina. Prevention of vasoconstriction during dynamic exercise is postulated as a mechanism that explains the previously reported evidence from noninvasive studies of improved myocardial blood flow after infusion of diltiazem during exercise.3 2
